EPIX- developing treatment to lower blood pressure.
"Discovered and designed using its PREDICT(TM) proprietary G-protein coupled receptor (GPCR) modeling and optimization technology, EPIX is developing PRX-08066 to provide both symptomatic improvement - through selective dilation of diseased pulmonary blood vessels - and to also slow disease progression - by inhibiting the thickening of the pulmonary artery vessels. EPIX believes PRX-08066 is the first 5-HT2B selective antagonist under development for pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD)."
.
He who loves money will not be satisfied with money, nor he who loves abundance with its income. This too is vanity.
-Eccl 5:10